Long Covid Solutions Congress – March 2022

Research collaboration on inflammatory molecules and clotting proteins. • 11:12

Focus on platelets and red blood cells interaction in long Covid. • 12:29

Identification of novel inflammatory molecules affecting symptoms. • 13:44

Role of platelet hyperactivation in pathological clotting in patients. • 14:00

Nutraceutical interventions showed significant improvement in lung function and reduction of abnormal findings in clinical trials. • 18:00

Combination of natural molecules in nutraceutical form led to rebalancing of the organism and restoration of organ functions. • 19:07

Clinical observations indicated reduction in symptoms like fatigue, hypoxia, sore throat, and myalgia with nutraceutical intervention. • 21:36

Significant increase in bioavailability of nutraceuticals was achieved, leading to improved efficacy in balancing body parameters. • 24:52

Nutraceutical intervention demonstrated safety with no adverse events reported during clinical trials. • 27:22

Patients struggle globally to access medical help for long Covid. • 40:52

Challenges in receiving referrals and accessing long Covid clinics in the UK. • 41:04

Difficulty in getting support from the medical community for long Covid treatments. • 41:23

Research on help apheresis and triple therapy shows promising results in treating long Covid patients. • 48:49

Early intervention within 3-6 months of onset may prevent microclots and alleviate symptoms. • 51:16

Persistent microclots can lead to long-term damage and autoantibody issues if left untreated. • 54:03

Symptoms of neurological damage may not be detectable through common imaging tests; biochemical level damage is crucial. • 1:06:43

Discussion on the limitations of imaging tests in detecting early neurological damage. • 1:07:03

Lack of specific diagnostic tools for biochemical injuries in neurons. • 1:07:03

Symptoms reported by patients should be investigated as they can indicate underlying issues. • 1:07:15

Importance of trusting patient-reported symptoms in diagnosing neurological issues. • 1:07:43

Biochemical injuries release chemicals that may be detected in blood if they cross into the venous system. • 1:08:03

Exploration of biochemical markers released by injured cells as potential diagnostic indicators. • 1:08:09

Mast cell activation syndrome may be exacerbated by acute Covid, leading to diverse symptoms. • 1:13:58

Early and effective treatment of acute Covid is crucial to reduce the risk of long Covid. • 1:16:06

Genetic condition of mast cell activation affects up to 17% of the population. • 1:17:03

Symptoms of long Covid include hypertension, brain fog, anxiety, fatigue, and more. • 1:18:37

Approach to managing long Covid involves addressing methylation, detoxification, inflammation, and more. • 1:19:31

Patients are advised to follow a low histamine diet and use type 1 antihistamines. • 1:20:05

Differentiating between long Covid, ME/CFS, fibromyalgia, and post-vaccination symptoms is crucial. • 1:20:17

Gradual medication approach: starting with loratadine, then adding fexofenadine, and finally mast cell stabilizers. • 1:20:24

Consideration of probiotics for gut microbiome imbalance in patients with chronic inflammatory diseases. • 1:21:59

Use of low dose naltrexone (LDN) for neurological symptoms like tingling pains. • 1:23:10

Identification of similarities in cytokine profiles among ME/CFS, long Covid, and post-vaccination long haulers. • 1:31:43

Treatment targeting CCR5/CCL5 pathways and fractalkine receptors to alleviate symptoms in long Covid and post-vaccination individuals. • 1:32:00

Classification of chronic inflammatory diseases based on distinct cytokine nodes for tailored therapy. • 1:33:23

Promising results of using maraviroc and statins in reducing symptom severity and correlating with biomarkers. • 1:34:19

Biomarkers like soluble CD40 ligand and VEGF show correlation with neurodisease and dysautonomia symptoms. • 1:34:34

Treatment with Maravarak and statins leads to statistically significant decrease in symptoms like dysautonomia and fatigue. • 1:34:41

Fatigue in long COVID patients correlates with TNF alpha and interleukin-2 levels. • 1:35:14

Correlation between biomarkers and symptoms aids in understanding treatment response in long COVID. • 1:35:55

Differentiating long COVID cases based on immune dysregulation and latent infections is crucial for tailored treatment. • 1:39:05

Early recognition and treatment of mast cell activation syndrome can prevent prolonged symptoms in long COVID. • 1:40:26

Low histamine diet may be necessary for managing MCAS symptoms, potentially long-term. • 1:44:02

Resources like marcelaction.org and Dr. Tanya Dempsey’s website offer support and information on MCAS. • 1:45:17

Collaboration between patients and doctors can improve recognition and management of MCAS in long COVID. • 1:46:10

High immunoglobulin E levels may indicate mast cell activation in long COVID patients, requiring specific treatment approaches. • 1:47:05

Classification of long Covid into different categories is vital for accurate treatment interventions. • 1:48:09

Differentiating between primary and secondary causes of pathology in long Covid is crucial. • 1:48:21

Developing simple tests to categorize patients based on markers can improve treatment efficacy. • 1:48:43

Challenges in interpreting serology for chronic viruses like EBV highlight the need for accurate categorization. • 1:49:03

Debate on viral persistence versus viral debris in long Covid, emphasizing the importance of accurate understanding. • 1:52:05

Focus on proteomics to uncover the role of proteins in autoimmune diseases and potential treatment avenues. • 1:57:15

Investing in biomarkers for neurological damage in long Covid to understand and address the associated symptoms. • 2:00:05

Long Covid patients often have pre-existing gastrointestinal issues. • 2:01:12

Research suggests Long Covid involves viral-mediated autoimmune responses. • 2:01:19

Clotting issues in Long Covid patients may be linked to inflammatory molecules. • 2:02:35

Patients with Long Covid may benefit from targeting microclots for diagnostics and treatment. • 2:03:58

Identifying specific molecular origins of symptoms in Long Covid is crucial for effective treatment. • 2:04:05

Classification of Long Covid subtypes is essential for tailored treatment strategies. • 2:08:01

Addressing stigma around Long Covid requires accurate reporting in media and scientific validation. • 2:12:30

Good science and proper media coverage can help change perceptions of Long Covid. • 2:12:48

Validation of Long Covid conditions through research can combat denial and stigma. • 2:13:13

Funding challenges may hinder research efforts in understanding and treating Long Covid. • 2:13:24

Long Covid lacks clear protocols and medical acceptance, leading to psychologizing of patients. • 2:13:45

Collaboration and research trials are crucial to develop effective treatments for Long Covid. • 2:16:01

Chronic Fatigue Syndrome serves as a cautionary example of the consequences of not addressing root causes. • 2:25:00

Focusing on treating causes rather than symptoms is essential in addressing complex conditions like Long Covid. • 2:26:19

Comprehensive research into biomarkers, co-infections, and biological pathways is necessary for a deeper understanding of Long Covid. • 2:28:41

Collaboration among doctors and researchers is crucial for understanding and treating long Covid. • 2:29:15

Nutraceutical interventions and research on epigenetic settings are explored for potential benefits. • 2:29:26

Efforts to identify molecules for rebalancing the body and supporting conventional treatments are underway. • 2:30:00

Challenges in medical fraternity highlighted, emphasizing the need for deeper disease understanding. • 2:33:01

Media’s impact on patient support and research dissemination discussed, highlighting both positive and negative aspects. • 2:37:14

Global collaboration for research and trials on long Covid encouraged among international peers. • 2:40:38

Patient reluctance to discuss symptoms addressed, emphasizing the role of social media in connecting and supporting individuals. • 2:41:47

Emphasis on collaboration for future progres. • 2:42:45

Acknowledgment of eye-opening discussio. • 2:43:00

Hope for clearer answers in the futur. • 2:43:15

Recognition of critical role in finding solution. • 2:43:24

Encouragement for continued treatment developmen. • 2:43:34